TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
Last trade$1.33
Day change$0.00 (0.00%)
Day range$1.30 – $1.44
Volume344,163
Market cap$87M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$87.46M
Price / earnings
—
Price / book
4.73×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.34×
Profitability
Earnings per share
-$0.47
Return on assets
-96.49%
Return on equity
-165.57%
Dividend yield
0.01%
Liquidity and leverage
Debt / equity
0.28×
Current ratio
0.18×
Quick ratio
0.18×
Cash ratio
0.11×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$29.9M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for HURA, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.14M
$2.3M
-$1.56M
$1.76M
$1.86M
$2.02M
$1.28M
Research and development
$6.62M
$5.23M
$6.06M
$4.97M
$4.93M
$4.58M
$3.98M
Total operating expenses
$8.76M
$7.53M
$8.17M
$6.73M
$9.88M
$7.02M
$5.69M
Operating income
-$8.76M
-$7.53M
-$8.17M
-$6.73M
-$9.88M
-$7.02M
-$5.69M
Interest expense
-$467.63K
-$27.97K
-$608.75K
-$16.53K
$0
$0
-$522.84K
Income before taxes
-$9.22M
-$7.54M
-$6.76M
-$7.1M
-$9.52M
-$6.66M
-$6M
Income taxes
$0
$0
$0
$0
$0
$0
$0
Net income
-$9.22M
-$7.54M
-$6.76M
-$7.1M
-$9.52M
-$6.66M
-$6M
Net income attributable to common shareholders
-$9.23M
-$7.54M
-$6.76M
-$7.1M
-$9.53M
-$6.67M
-$6M
EBITDA
-$8.74M
-$7.51M
-$4.47M
-$6.71M
-$6.78M
-$6.58M
-$5.24M
Basic earnings per share
-$0.14
-$0.13
-$0.13
-$0.14
-$0.21
-$0.15
-$0.16
Diluted earnings per share
-$0.14
-$0.13
-$0.13
-$0.14
-$0.21
-$0.15
-$0.16
Recent news
Company coverage with links to the original publishers.
The Merkel cell carcinoma market is expected to grow significantly between 2025-2034, driven by rising global incidence, increased awareness, and innovative treatment developments like immunotherapies and targeted therapies.
TuHURA Biosciences advanced its immuno-oncology pipeline in Q2 2025, launching a Phase 3 trial for IFx-2.0 in Merkel cell carcinoma and completing the Kineta acquisition. The company raised $15.5 million in equity financing to support ongoing clinical development.
Halper Sadeh LLC is investigating potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to the proposed sales and mergers of The Shyft Group, MoneyLion Inc., TuHURA Biosciences, Inc., and Kineta, Inc.
Halper Sadeh LLC is investigating several companies, including MoneyLion Inc., Patterson Companies, Inc., TuHURA Biosciences, Inc., and Kineta, Inc., for potential violations of securities laws and breaches of fiduciary duties to shareholders related to proposed mergers and acquisitions.
The M&A Class Action Firm is investigating the proposed merger between Kineta, Inc. (OTC: KANT) and TuHURA Biosciences, Inc. The firm is looking into the terms of the agreement, where TuHURA would acquire the rights to Kineta's KVA12123 antibody.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.